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1. Introduction
Peptic ulcer (gastric or duodenal ulcer) is one of the most common disorders affecting the
gastrointestinal system. The lifetime cumulative incidence of peptic ulcer disease is more than
10% of adult population in western countries (Ofman et al., 2000). The pathophysiology of
peptic ulcer disease is an imbalance between mucosal defense factors (bicarbonate, mucin,
prostaglandin, nitric oxide and other peptides and growth factors) and injurious factors (acid
and pepsin). The management and prevention of these acid-related disorder are possible either
by decreasing the level of gastric acidity or by enhancing mucosal protection (Brunton et al.,
2008). Various factors, including genetic, diet, pharmacologic and psychologic might contrib‐
ute to peptic ulcers (Wyatt, 1989). Helicobacter pylori (H. pylori) is a prominent etiologic factor
influencing peptic ulcer disease (Hauser et al., 2005). Regarding the fact that H. pylori play a
dominant role in the majority of peptic ulcers, prevention of relapse is focused on eradication
of this organism from the stomach.
Nowadays it is believed that, H. pylori and non-steroidal anti-inflammatory drugs (NSAID)
are the two major contributing factors causing peptic ulcer disease (Graham, 1996). H. pylori
is found in approximately 100% of chronic active antral gastritis cases; 90% to 95% of duodenal
ulcer patients and 50% to 80% of gastric ulcer patients (Kluwer, 2004). Owing to the fact that
chronic infection with H. pylori weakens the natural defenses of the lining of the stomach
against the ulcerating action of acid, medications that neutralize stomach acid, antacids, and
medications that decrease the secretion of acid in the stomach such as H2-blockers and proton
pump inhibitors (PPIs) have been used effectively for many years to treat ulcers. Obviously,
antacids, H2-blockers and PPIs not only would have no effect on H. pylori eradication from the
stomach, but also the ulcers are frequently returned promptly after these medications are
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discontinued. Accordingly, eradication of H. pylori also is important in the treatment of the
pylori-related ulcers which could be achieved through the commonly used antibiotics.
Figure 1. H. pylori in peptic ulcers.
Not surprisingly, the wide range of effective medicinal agents available today is one of the
greatest scientific achievements. Regardless of the effectiveness and safety of the medicines
embedded in dosage forms, the pharmaceutical concept of the latter is growing to be ever more
eminent in the management of different diseases. The oral dosage forms of the medications
available for H. pylori eradication, typically, possess several physiological restrictions such as
non-uniform drug absorption profiles, incomplete drug release and shorter residence time of
the dosage form in the stomach (MotlekarYouan, 2006; Adibkia et al., 2011; GisbertCalvet,
2011). Rate of the transition for a dosage form through the gastrointestinal (GI) tract is highly
affected by the physiological properties of the GI tract as well as the formulation properties
(Bardonnet et al., 2006a; Khobragade et al., 2009). Hence, suitable pharmaceutical dosage forms
in H. pylori eradication is also an important basic principle of the drug delivery system
dominating these constraints and offering a proper delivery strategy that would function
independent of the digestive state, clinical condition, or GI motility of the individual. Since the
bioavailability of drugs often depends on the GI transit rate of the dosage form, it appears
necessary to establish an appropriate sustained release system for drug delivery (Hu et al.,
2010; JavadzadehHamedeyazdan, 2012).
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2. Prolongation of GI retention
Scientific and technological advancements have been made in the research and development
of different types of drug delivery systems. Keeping up with the rapid development in
designing novel drug delivery systems, it is advisable to explore the existing delivery concept
and new intra gastric delivery systems which would be expected to overcome the current
medication limitations of the treatment of H. pylori associated peptic ulcer. It is obvious that
formulating dosage forms that retained in the stomach for a prolonged and predictable period
of time seem to be advantageous in H. pylori eradication.
The most feasible method for achieving a prolonged and predictable drug delivery in the GI
tract is to control the gastric residence time by gastro retentive and sustained release dosage
forms that have some beneficial in safety and efficacy over normal release systems. This
method of application is especially helpful in delivery of sparingly soluble and insoluble drugs
used in H. pylori eradication. It is acknowledged that, as the solubility of a drug decreases, the
time available for drug dissolution becomes less adequate and so the transit time becomes an
important factor affecting drug absorption in drugs with lower solubility. Other drug candi‐
dates suitable for gastroretentive drug delivery systems include those drugs that are locally
active in the stomach, drugs with narrow absorption window in GI tract, drugs that are
unstable in the intestinal or colonic environment, drugs that act locally in the proximal part of
GI tract or disturb normal colonic microbes like antibiotics and also drugs that exhibit low
solubility at high pH values. Concerning the pharmacotherapy of the stomach through local
Figure 2. Major factors causing mucosal damage and ulceration (Peura, 2004).
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drug release of gastroretentive dosage forms, bringing about high levels of drug concentrations
at the gastric mucosa (eradication of H. pylori from the submucosal tissue of the stomach), and
treating stomach and duodenal ulcers, gastritis and oesophagitis, the risk of gastric carcinoma
would be drastically reduced. In contrast, there are drugs that do not fit in gastroretentive drug
delivery systems; Drugs that have very limited acid solubility, drugs that suffer instability in
the gastric environment, and drugs intended for selective release in the colon should follow
other techniques of drug delivery to reach for their intended site of action. Hence, gastrore‐
tentive dosage forms despite providing rather constant drug concentrations in the bloodstream
for longer periods of time do not fulfill this benefit with several groups of drugs (Javadzadeh‐
Hamedeyazdan, 2012; Pahwa et al., 2012b).
One of the advantages of the sustained release dosage forms is that medication is administered
less often than other dosage forms reducing fluctuations of drug concentration in the blood‐
stream. As a result, the patient is not repeatedly subjected to different levels of drug which are
less or more than adequate. Nor does the blood chemistry undergo frequent chemical imbal‐
ances, which might be risky to the patient's health. Additionally, through gastroretentive
dosage forms not only the bioavailability and therapeutic efficacy of drugs are improved but
also it may allow for a possible reduction in the dose because of the steady therapeutic levels
of drugs. Drugs that have poor solubility in higher pH, absorption windows in stomach,
requiring local delivery in stomach could be delivered ideally to the site of action by the
gastroretentive formulations. On the other hand, drugs that cause irritation to gastric mucosa
and the ones meet first-pass metabolism or have stability problems in gastric fluids are not
appropriate for these kinds of drug delivery systems (JavadzadehHamedeyazdan, 2012;
Pahwa et al., 2012a; Pawar et al., 2012).
In brief, gastric retention is a means to enable a delivery strategy that will function irrespective
of the digestive state, clinical condition, or GI motility of the individuals with longer drug
residence time in the stomach being advantageous in superior drug bioavailabilities and also
in certifying local action of some drugs in the upper part of the GI tract, that are used in H.
pylori eradication (Bardonnet et al., 2006b; Nama et al., 2008; Badhan et al., 2009; Shah et al.,
2009; AdebisiConway, 2013).
3. H. pylori associated peptic ulcer
3.1. Acidic condition of stomach
The human stomach can produce and secrete about 2.2 to 3 L of gastric acid per day with basal
secretion levels being typically highest in the evening. Normally no bacteria or viruses can
survive in this medium that is composed of digestive enzymes and concentrated hydrochloric
acid. Consequently, stomach has been regarded as a sterile ingestion organ for its hostile and
acidic environment that could be considered as a barrier for invasion of various microorgan‐
isms. However, this notion has been totally changed since H. pylori as a major cause of peptic
ulcer disease and gastritis in human was firstly isolated by Marshall and Warren in 1983 (Yang
et al., 1999). H. pylori, a spiral-shaped gram-negative rod, is classified as Campylobacter
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pyloridis due to its similar histological and growth properties to the Campylobacter species.
Based on the unique morphological and biochemical characteristics, Campylobacter pyloridis
was regrouped into a new genus Helicobacter (Brooks et al., 2004).
3.2. Pathogenesis of H. pylori
H. pylori is associated with antral gastritis, peptic ulcer disease (gastric and duodenal ulcer
disease) and gastric carcinoma, however, it initially induces chronic gastritis to develop peptic
ulcer rather than directly causing the ulcer disease (Wyatt, 1989). Ever since, H. pylori grows
optimally at a pH of 6-7, it would not grow at the pH of the gastric lumen. Gastric mucus is
relatively impermeable to acid and has a strong buffering capacity so deep mucus layer near
the epithelial surface where the pH is about physiologic of 7.4 is an appropriate place for H.
pylori growth. The bacterium produces a protease modifying the gastric mucus to reduce the
ability of acid to diffuse through the mucus. In addition, H. pylori also has potent urease
activity, which yields production of ammonia and further buffering of acid, which may directly
damage the cells, too (Brooks, Butel et al., 2004; Abe et al., 2011). Although, the mechanisms
by which H. pylori causes mucosal inflammation and damage, are not well known but they
may involve both bacterial and host factors. Compared to other infectious diseases, the H.
pylori associated morbidity is relatively high, which is about 10% for peptic ulcer disease and
0.5% for gastric adenocarcinoma (Kusters, 2001). Once H. pylori eradication has been achieved,
re-infection rates are less than 0.5% per year, and ulcer recurrence rates are dramatically
reduced (Kluwer, 2004). Since, there is not any clear hypothesis about spread of H. pylori,
prevention is rather difficult issue. Then in treatment of peptic ulcer disease, clinicians are
logically focusing on the eradication of H. pylori (Ables et al., 2007; Yamaoka, 2010).
Figure 3. Pathogenesis of H. pylori (Kusters et al., 2006).
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3.3. Treatments for H. pylori associated peptic ulcer disease
Basically, the goals for peptic ulcer treatments have been defined as: alleviation of symptoms,
healing of the ulceration, prevention of recurrence of ulcer. Primarily, before the bacterium
was found, it was believed that stomach ulcers occur when excess acid damaged the gastric
mucosa so the treatment was based on reduction or neutralization of that acid (Gisbert et al.,
2010; GisbertPajares, 2010). Patients were treated with long-term suppressive therapy by
giving acid-blocking medications, for instance, H2-blockers and, more recently, proton pump
inhibitors (BreuerGraham, 1999). This kind of treatment could certainly relieve ulcer-related
symptoms, heal gastric mucosal inflammation and even heal the ulcer. Unfortunately, it has a
high recurrence rate just owing to the lack of basic treatment of the infection and eradication
of the bacterium, H. pylori (Brunton, Parker et al., 2008). The identification of H. pylori, and
understanding of H. pylori associated peptic ulcer disease have greatly changed therapeutic
regiments covering peptic ulcer disease. Eradication of H. pylori is now recognized to be the
correct approach in the treatment of the disease (Yang, Eshraghi et al., 1999; Chuah et al.,
2011). The treatment of peptic ulcer with antibiotics is recognized as the choice treatment for
patients (Beales, 2001). Savings of costs and time are the major benefits of this protocol to
therapy with acid reducing medications. The same drug and dosage regimens could be applied
to the treatment for both gastric and duodenal ulcer as there are no important differences
between these two ulcer diseases (DzieniszewskiJarosz, 2006). Antibiotics and agents used to
eradicate H. pylori, attack three main areas, i.e. the bacterium cell wall, the ribosome and
nuclear DNA. For instance, metronidazole, a nitroimidazole antiprotozoal drug that also has
potent antibacterial activity against anaerobes, including bacteroides and clostridium species,
can disrupt the bacterial DNA helix preventing replication and interrupting gene expression,
bismuth salt may disrupt bacterial cell wall or membrane (Malfertheiner, 1996).
3.3.1. Combination therapy
Although H. pylori is sensitive to many antibiotics in vitro, this sensitivity is not correlated with
eradication of the organism in vivo (Drumm, 1990). Recurrence of the infection is common after
treatment of H. pylori by bismuth alone or monotherapy antibiotic (Rauws et al., 1988; Oderda
et al., 1989; Chang et al., 2009). It has been postulated that the failure of antibiotic monotherapy
to clear H. pylori in vivo may be due to the lack of efficacy of the antibiotics in the acid envi‐
ronment of the stomach (Drumm, 1990). Other possible reason of failure could be the area that
H. pylori colonized and resistance to bacteria. As a result of failure of single antibiotic therapies,
combination regiments are suggested to increase the rate of H. pylori eradication. Nonetheless,
many regimens for H. pylori eradication have been proposed, the ideal regimen in this setting
should achieve a cure rate of >80% (Brunton, Parker et al., 2008).
3.3.2. Triple combination therapy
Triple combination therapy, using two antibacterial antibiotics and a proton pump inhibitor,
had achieved a high eradication rate and seems to be the most effective regimens for H.
pylori eradication (AxonMoayyedi, 1996; Ishizone et al., 2007). Proton pump inhibitors promote
eradication of H. pylori through several mechanisms: direct antimicrobial properties (minor);
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raising intra-gastric pH and lowering the minimal inhibitory concentrations of antibiotics
against H. pylori. One of the principal treatment regimens consists of a 10–14 day regimen of
"triple therapy": a proton pump inhibitor (standard dose, b.i.d.), clarithromycin, (500 mg, b.i.d.)
and amoxicillin (1 g, b.i.d.). For patients who have allergy to penicillin, metronidazole, 500 mg
twice daily, should be substituted for amoxicillin. Moreover, after completion of triple therapy,
the proton pump inhibitor has been recommended to be continued once daily for a total of 4–
6 weeks to ensure complete ulcer healing (Katzung, 2006). Other triple therapies that are being
mentioned in other reference includes combinations of bismuth salts and various antibiotics
(Rauws, Langenberg et al., 1988).
3.3.3. Quadruple combination therapy
In the case of H. pylori eradication quadruple therapy has been offered for 14 days: Proton
pump inhibitor twice a day, metronidazole 500 mg three times daily, bismuth subsalicylate
525 mg, tetracycline 500 mg four times daily or H2-receptor antagonist twice a day, bismuth
subsalicylate 525 mg, metronidazole 250 mg, tetracycline 500 mg four times daily (Brunton,
Parker et al., 2008). Antibiotics from systemic circulation have to traverse the epithelial layer
(Malfertheiner, 1996; Hsu et al., 2011). Seeing as, in systemic administration of drugs the gastric
emptying makes the effective local concentrations of drugs difficult to maintain, the effects of
drug is not local and is through its systemic absorption, the frequent doses of oral antibiotics
are required leading to higher drug dosages, lower patient compliance, and adverse drug
effects.
3.4. Drug delivery systems for H. pylori eradication
3.4.1. Importance of drug delivery systems in treatment of diseases
It is judicious to be reminiscent of the GI tract being a primary site for the absorption of drugs
with a variety of limitations making the in vivo performance of drug delivery systems uncer‐
tain. Despite tremendous advancement in drug delivery, the oral rout still remains the
preferred route for the administration of therapeutic agents in consequence of the low cost of
therapy, and ease of administration, as well as patient compliance. However, oral dosage forms
hold several physiological restrictions like non-uniform absorption profiles, incomplete drug
release and shorter residence time of the dosage form in the stomach (Adibkia, Hamedeyazdan
et al., 2011). Undoubtedly, rate of drug transition through the gastrointestinal (GI) tract is
highly controlled by the physiological properties of the GI tract as well as the formulation
properties. Since, bioavailability of drugs in this route of administration often depends on the
GI transit rate of the dosage form it is of value to distinguish between an appropriate drug
delivery system for an especial objective in treatment of diseases. Acquiring a clear notion of
why certain medications are prone to problems in reaching the desired efficiency and bioa‐
vailability, to dominate the relative constraints offering successful medication therapy
recalling some fundamental characteristics of the stomach would be of note.
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3.4.2. Stomach and drug delivery systems
As far as we know, the stomach is a muscular, hollow, dilated part of the alimentary canal
which functions as an important organ of the human body located between the esophagus and
the small intestine. Surface epithelium of stomach retains its integrity throughout the course
of its lifetime, even though it is constantly exposed to a high concentration of hydrochloric acid
and powerful enzymes. This self protection mechanism is due to the fact that the specialized
goblet cells located in the stomach and continuously secrete a large amount of mucus that
remains closely applied to the surface epithelium (Chein, 1992). In general, stomach is an
important site of enzyme production with small surface area, offering an imperfect site of
absorption (Chein, 1992). The main function of stomach is to store food temporarily, grind it,
and then release it slowly in to the duodenum. The process of gastric emptying occurs both
during fasting and fed states; however, the pattern of motility differs markedly in the two
states. Fasted state is characterized by an inter-digestive series of electrical events which cycle
both through the stomach and small intestine every 2–3 h which is called the inter-digestive
myoelectric cycle or migrating myoelectric complex (Fell, 1996). In the fed state, the gastric
emptying rate is slowed since the feeding results in a lag time prior to the onset of gastric
emptying, depending upon the physiological state of the subject and the design of pharma‐
ceutical formulation, the emptying process can last from a few minutes to 12 h. Alterations in
gastric emptying occurs due to factors such as age, race, sex, and disease states, as they may
seriously affect the release of a drug from the drug delivery system (SinghKim, 2000).
The complex and highly variable nature of gastric emptying process making the in vivo
performance of conventional drug delivery systems uncertain draw researchers’ attention to
find a clue and dominate these constraints and present suitable drug delivery strategies that
would serve independent of the digestive state, clinical condition, or GI motility of the
individual. Conventional oral dosage forms provide a specific drug concentration in the
systemic circulation without offering any control over the rate of drug delivery, whilst
controlled-release drug delivery systems provide drug release at a predetermined, predictable,
and controlled rate of drug release (Hwang et al., 1998). Nevertheless, in some cases the
insufficient residency of drugs in the vicinity of absorption site for the life time of drug delivery
restricts the use of controlled-release drug delivery systems. The inadequate drug residence
in the vicinity of absorption site might arise from differences in GI transit time of drugs in
individuals, and physical properties of the object ingested as well as the physiological
conditions of the alimentary canal. Correspondingly, medications with sustained drug release
forms have some benefits over normal release systems in safety and efficacy in reducing the
frequency of drug dosage, together with the diminished incidence of adverse drug reactions.
Hence, if medications used in H. pylori eradication therapy are used in terms of sustained
release dosage forms some advantages are fulfilled seeing as the medications are administered
less often than other dosage forms, fluctuations of drug concentration in the blood would be
reduced, and the patient is not repeatedly subjected to amounts of the drug which are less or
more than adequate, nor the blood chemistry experience frequent chemical imbalances, which
might be detrimental to the patient's health (Klausner et al., 2003; Javadzadeh et al., 2007; Tang
et al., 2007; Javadzadeh et al., 2009; Javadzadeh et al., 2012). Several methods have been
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developed for extension of GI transit time via enhancing the residence time of drug delivery
systems in the stomach.
3.4.3. Floating drug delivery systems
One of the approaches followed to extend the residency of medications in the stomach is
floating dosage forms with lower density than the gastric fluids to be capable of floating on
the gastric juice in the stomach (SinghKim, 2000; Adibkia, Hamedeyazdan et al., 2011).
According to the mechanism of buoyancy, two evidently different technologies are applied in
development of floating dosage forms, effervescent and non-effervescent systems. In general,
the principle rule is indelible in all approaches and that is to float on gastric juice with a specific
density of less than 1.004 g/cm of the gastric juice in the stomach.
Figure 4. Effervescent floating drug delivery system in the stomach
Besides, multi-particulates of floating dosage forms consisting of small discrete units in which
the active substance is offered as a number of small independent subunits are less reliant on
gastric emptying, bringing about less inter and intra-subject variability in GI transit time.
Moreover, they are also well distributed and less likely to cause local irritation. Nowadays,
much emphasis is being laid on the development of multi particulate dosage forms rather than
single unit systems due to potential benefits of them such as increased bioavailability, reduced
risk of systemic toxicity, reduced risk of local irritation as well as predictable gastric emptying
(MohamadDashevsky, 2007; GuptaPathak, 2008).
A number of factors that affect gastric emptying of a dosage form, such as density, size, and
shape of dosage form, concomitant intake of food and drugs such as anticholinergic agents
(e.g., atropine, propantheline), opiates (e.g., codeine), prokinetic agents (e.g., metoclopramide,
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cisapride), and biological factors like gender, posture, age, body mass index, and disease states
(e.g., diabetes, Crohn’s disease) could be controlled by these floating dosage forms providing
a more convenient medication therapy (SinghKim, 2000).
These systems are also appropriate for drugs which are locally active to the gastric mucosa in
the stomach, such as administration of metronidazole (MZ) as an antibiotic for H. pylori
eradication in the treatment of peptic ulcer disease (Murata et al., 2000; Rajinikanth et al.,
2007; RajinikanthMishra, 2007; RajinikanthMishra, 2008). Treatment of H. pylori infection by
topical administration of antimicrobial agents has been reported. In order to avoid the side
effects of standard triple therapy, Satoh used a technique of instilling a combination of bismuth
subnitrate, amoxicillin and metronidazole into the stomach via a naso-gastric tube for 1 hour.
He found that topical therapy was highly successful with high eradication rate of H. pylori and
none-ulcer dyspepsia as well. Although this local administration successfully avoids some of
the side effects of standard triple therapy, it is inconvenient and still complicated to patient
when compared to oral dosage delivery system (Satoh, 1996). Elsewhere, the hydrodynami‐
cally balanced delivery system of Clarithromycin was developed which, after oral adminis‐
tration had the ability of prolonged gastric residence time with the desired in vitro release
profile for the localized action in the stomach, in the treatment of H. pylori mediated peptic
ulcer. In this study, wet granulation technique was applied for preparing of floating tablets of
Clarithromycin. The proportion of sodium bicarbonate was varied to get the least possible lag
time, also the polymer part varied to get the desired release. The formulation that developed
using 66.2% Clarithromycin, 12% HPMC K4M polymer, 8% sodium bicarbonate gave floating
lag time less than 3 min with a floating time of 12 h, and an in vitro release profile very near to
the desired release. In vivo radiographic studies also suggested that the tablet had increased
gastric residence time for the effective localized action of the antibiotic (Clarithromycin) in the
treatment of H. pylori mediated peptic ulcer. The mechanism of release of Clarithromycin from
the floating tablets was anomalous diffusion transport and followed by zero order kinetics
(Nama, Gonugunta et al., 2008). In another study by Pornsak Sriamornsak, oil-entrapped
calcium pectinate gel floating beads were prepared using selected oils that were floated
immediately and remained floating for 24 hours. They concluded that this lasting intra-gastric
buoyancy of a controlled release dosage form may also provide a suitable manner to deliver
drugs that are locally active to the gastric mucosa in the stomach and, hence, achieve a site-
specific therapeutic action (e.g., antibiotic administration for H. pylori eradication in the
treatment of peptic ulcer disease (Sriamornsak et al., 2004). Then again, in another study
Sriamornsak et al. evaluated the effects of some variables on release behavior of metronidazole
from floating emulsion gel beads of calcium pectinate. They detected a notable prolongation
drug release profile by coating the beads with Eudragit or by hardening with glutaraldehyde,
whereas no clear effect on drug release was obtained using PEG10000, glyceryl monostearate
and Eudragit as additives in the formulations (Sriamornsak, Thirawong et al., 2004; Sriamorn‐
sak et al., 2005).
Considering the fact that prolongation of the local availability of the antibacterial agents show
positive effects of increasing in the effectiveness of H. pylori treatment ensuring a high drug
concentration in the gastric mucosa, we had tried to formulate metronidazole in floating
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pharmaceutical dosage forms to encounter higher concentrations of the antibacterial agent in
the gastric mucosa and clarify the mechanism of the release obtaining a general kinetic model
for drug release profiles. In our previously published papers, we had reported the use of two
different mechanisms in preparation of metronidazole floating matrix tablets including: A low
density producing agent (gas generating agent/porous agent) and hydrocolloid-forming
polymer(s) (Asnaashari et al., 2011). Carbonate acted as the gas generating agent when it came
into contact with an acidic environment of the stomach under fed condition which got
entrapped inside the system, producing bubbles, decreasing the density of the formulation.
Preparing a low-density system using calcium silicate a characteristically porous structure
with many pores and a large pore volume which forms a porous buoyant system (Jain et al.,
2005). The hydrocolloids such as HPMC, carbopol, psyllium in the metronidazole formulations
were hydrated and formed a colloid gel barrier that controled the rate of drug release, around
its surface with thickness growing by time and increasing of volume due to hydration that in
a bulk density less than 1 g/cm3 remaining buoyant on the gastric fluid. The established
suitable release metronidazole floating matrix tablets could ensure a more localized drug
concentration which might be useful for H. pylori eradication. In other survey, we had prepared
alginate beads of metronidazole employing gas generating and porous agents followed by
physicochemical evaluations for the prepared formulations (Javadzadeh et al., 2010). Alginates
due to their high biocompatibility and nontoxic nature in oral administration that also
demonstrate protective effect on the mucous membranes of the upper GI tract are a remarkable
natural polymers found in brown algae that have been studied for a variety of biomedical
applications. Sodium-Alginate beads (Na-Alg) have been developed in recent years as a unique
vehicle for drug delivery. Alginates, which are naturally substances, are found in brown algae
and can be considered as block polymers, which mainly consist of mannuronic acid (M),
guluronic acid (G) and mannuronic-guluronic (MG) blocks. Alginate is known to be nontoxic
when taken orally and also have protective effect on the mucous membranes of the upper
gastrointestinal tract. The alginate beads with the structure of spherical gels are taken shape
through dropwise addition of aqueous alginate solution to the aqueous solution containing
calcium ions and/or other di and polyvalent cations (10). The pH dependent reswelling
property of dried alginate beads let them to be administrated as controlled release system in
gastrointestinal tract. The drug release from pharmaceutical dosage forms is a major determi‐
nant in their biological effect, thus evaluation of drug release kinetic is of paramount impor‐
tance in the field. The findings of our study revealed high compatibility of the alginate beads
in achieving a suitable floating pharmaceutical dosage forms which could control metronida‐
zole release from the beads with a definite kinetic of drug release. Identifying drug release
kinetics of a drug which is an important variable in obtaining one or two physically meaningful
parameters in relating the drug release parameter with important parameters such as in vivo
drug bioavailability is of substantial value in pharmaceutical manufacturing.
Hence, developing an efficient floating dosage form is reliant to a better understanding of the
relation among the physiological properties of the GI tract, formulation variables and the
performance of these floating systems in vivo and clinical stages, leading to a superior floating
drug delivery system in special cases like H. pylori eradication.
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4. Conclusion
Overall, developing an efficient floating dosage form for H. pylori eradication could be
established by the combination of two buoyancy mechanisms, gas generating systems with
swellable polymers, being advantages in view point of obtaining an appropriate floating lag
time and duration of buoyancy which guarantees the optimum efficiency of the pharmaceut‐
ical dosage form. Nonetheless, further investigations may focus on the compatibility of the
mentioned concepts in the interplay of the pharmacokinetic and pharmacodynamic parame‐
ters in vivo and also in clinical aspect to provide the effectiveness of the floating drug delivery
systems in H. pylori eradication therapies.
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